| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 3 | |
| #2 | United States | 3 | |
| #3 | Australia | 2 | |
| #4 | EAPO (Eurasian Patent Organization) | 2 | |
| #5 | Canada | 1 | |
| #6 | China | 1 | |
| #7 | United Kingdom | 1 | |
| #8 | Hong Kong | 1 | |
| #9 | Japan | 1 | |
| #10 | Republic of Korea | 1 | |
| #11 | WIPO (World Intellectual Property Organization) | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Measurement | |
| #3 | Micro-structure and nano-technology |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Medical preparations | |
| #3 | Analysing materials | |
| #4 | Nanostructure applications |
| # | Name | Total Patents |
|---|---|---|
| #1 | Wu Ming | 11 |
| #2 | Janssens Stefan | 11 |
| #3 | Trouet Andre | 2 |
| #4 | Trouet André | 2 |
| #5 | Andre Trouet | 1 |
| Publication | Filing date | Title |
|---|---|---|
| GB201819411D0 | Prodrugs comprising a tetrapeptidic moiety | |
| WO2014191553A2 | Human plgf-2 for the prevention or treatment of heart failure | |
| EP2938360A2 | Minimally toxic prodrugs |